Psoriatic arthritis mutilans seems to progress despite DMARD treatment and many patients have axial disease.
Outcomes in psoriatic arthritis should improve, representatives of the research body GRAPPA assert, now that patients are gaining a role in creating symptom measures and definitions.
Do European guidelines for axial spondylitis adequately address patient needs on the other side of the Atlantic?
Progress report from GRAPPA 2014.on the PsA BioDam (biomarkers of damage in psoriatic arthritis) study.
A third of psoriatic arthritis patients do not respond well to TNF-blockers and DMARDs. So there’s an urgent quest for new targeted drugs
At its 2014 annual meeting, GRAPPA continues development of criteria to help non-rheumatologists spot psoriatic arthritis.